Press Releases May 28, 2026 04:05 PM

CG Oncology to Present at Upcoming Investor Conferences in June

CG Oncology to Present at Major Healthcare Investor Conferences in June 2026

By Derek Hwang CGON

CG Oncology, Inc. announced that its Chairman, President & CEO, Arthur Kuan, will participate in presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference in early June 2026. The company focuses on developing innovative immunotherapies for bladder cancer and will webcast the sessions for investor access.

CG Oncology to Present at Upcoming Investor Conferences in June
CGON

Key Points

  • CG Oncology’s CEO will present at two significant healthcare investment conferences in June 2026.
  • The company specializes in late-stage clinical development of bladder cancer immunotherapies aiming to offer bladder-sparing treatments.
  • Live webcasts and archived presentations will be available to investors, enhancing transparency and engagement.

DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows:

Jefferies Global Healthcare Conference 
Date: Wednesday, June 3, 2026
Presentation Time: 10:30-11:00 AM ET
Location: New York, New York

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Presentation Time: 2:40-3:15 PM ET
Location: Miami, Florida

Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replays will be available shortly after the conclusion of the live presentations and archived for approximately 90 days.

About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts

Media 
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
[email protected]

Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
[email protected]


Risks

  • The company's products are still in clinical development, so regulatory and clinical trial risks remain high.
  • Market competition in oncology immunotherapies could impact CG Oncology’s commercial success.
  • Investor interest can be influenced by conference presentations but may not translate into immediate financial gains.

More from Press Releases

Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026